AllSight
Companies · ALMR · Laboratory Analytical Instruments · Earnings · Aug 10, 2026

Revenue surged, but heavier spending keeps the read firmly mixed

Alamar Biosciences, Inc. (ALMR) — what happened, in plain English, and what it means versus what the market expected.

There is no clean published Q2 revenue benchmark to call a beat or miss. Available public estimate pages identify analyst coverage but do not provide a usable Q2 revenue consensus in the accessible results, while the company had not issued full-year 2026 guidance as of its May 8 report. The appropriate anchor is therefore the prior quarter's $26.0 million revenue and the market's broad expectation for continued rapid post-IPO growth—not the company's promotional wording.

The top line continued to outperform its own recent pace. Q2 revenue reached $29.4 million, up 82% year over year and roughly 13% above Q1's $26.0 million. Consumables were the clear engine at $15.5 million, up 147%, while instruments grew 35% to $7.8 million and services rose 49% to $6.2 million (Revenue by source). That mix matters because consumables carry better economics and support a recurring pull-through model.

MetricQ2 2026Q2 2025Change / context
Total revenue$29.4M$16.2M+82% (Income Statement)
Instruments$7.8M$5.8M+35% (Revenue by source)
Consumables$15.5M$6.3M+147% (Revenue by source)
Services$6.2M$4.1M+49% (Revenue by source)
Gross margin60%53%+7 percentage points (Financial Results)
Operating expenses$31.3M$16.5M+89% (Income Statement)
Operating loss$(13.5)M$(7.9)MLoss widened (Income Statement)
Net loss$(13.2)M$(7.0)MLoss widened (Income Statement)
Cash, investments and restricted cash$256.3M—As of June 30, 2026 (Balance Sheets / Financial Results)

The profitability improvement is real at the gross-profit level, but not yet reaching the bottom line. Gross margin expanded to 60% from 53% as consumables became a larger share of sales and manufacturing efficiency improved (Financial Results). However, operating expenses rose 89%, faster than revenue, driven by hiring, infrastructure, R&D and public-company costs; operating loss consequently widened to $13.5 million (Income Statement). Stock-based compensation also increased to $3.3 million from $0.7 million (Stock-based compensation table), so the quarter shows operating leverage potential rather than delivered operating leverage.

The new guidance is constructive but not a clear upside reset. Full-year revenue guidance of $116 million to $120 million implies a $118 million midpoint and 59% growth over 2025 (2026 Guidance). With $55.5 million recorded in the first half (Income Statement), the company needs $60.5 million to $64.5 million in the second half—roughly $30.3 million to $32.3 million per quarter—to reach the range. That requires continued sequential growth, but the filing does not say the range was raised from an earlier forecast; it is the first formal full-year guide, so its signal is more about establishing a credible growth path than delivering a measurable guidance beat.

Net read: strong demand, better mix, but still an investment story rather than an earnings story. The revenue trajectory and consumables acceleration are better than a merely steady-growth outcome, and the $256.3 million liquidity position materially supports continued investment (Balance Sheets). But without a substantiated consensus comparison—and with operating losses widening—the filing earns a mixed read: commercially strong, financially still dependent on future scale to convert growth into earnings.

Read the original 8-K on SEC EDGAR ↗
More from Alamar Biosciences, Inc. (ALMR)
Sep 1, 2026Alamar adds Robert Ragusa to board, but filing offers no business catalystAll ALMR filings, decoded →
Related companies in Laboratory Analytical Instruments
Latest across the market
ACNAccenture earnings beat as Q4 revenue clears guidance, but FY27 growth stays measuredROPRoper Technologies adds NTT DATA CEO to board, but brings no operating changeIIPRIIPR loan increase funds Alewife buildout, but locks in 14% debtGTGoodyear executive change: controller exits as internal successor takes overGLUEMonte Rosa GFORCE-1 results clear safety bar, but ASCVD Phase 2 moves to 2027MODModine signs tax agreement for Gentherm spin-off, locking in closing mechanicsBrowse all companies, decoded →
Open live on AllSight — the whole market, decoded →
AllSight turns SEC filings into plain-English, neutral reads and objective market context. We explain what happened and how it lands versus expectations — we do not give investment advice or predict prices. Decoded straight from the filing; check it against the source.
Analysis by AllSight · Editorial standards & method · Contact